Comparative Pharmacology
Head-to-head clinical analysis: NIZORAL versus VAGISTAT 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NIZORAL versus VAGISTAT 1.
NIZORAL vs VAGISTAT-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal CYP51 (lanosterol 14α-demethylase), blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Tioconazole is an imidazole antifungal that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and fungal growth.
Ketoconazole 200 mg orally once daily with food. For severe infections, increase to 400 mg once daily. Duration depends on indication.
One 300 mg vaginal suppository administered as a single dose.
None Documented
None Documented
Biphasic elimination: initial half-life ~2 hours, terminal half-life 6–10 hours in adults with normal hepatic function; prolonged in hepatic impairment.
The terminal elimination half-life is approximately 5-7 days, reflecting prolonged vaginal retention and slow systemic absorption.
Approximately 70% of the dose is excreted unchanged in feces via biliary elimination, and about 20–35% is excreted in urine, with less than 1% as unchanged drug in urine.
Approximately 50% is excreted unchanged in feces via biliary elimination; less than 1% is excreted unchanged in urine.
Category C
Category C
Azole Antifungal
Azole Antifungal